Search research articles
Contact Us
Filters
Showing results (121-130 of 160) with videos related to
Page
of 16
Sort By:
Plos One
|
May 25, 2019
Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer
Willemijn S M E Theelen, Thomas Kuilman, Katja Schulze, et al.
Oncoimmunology
|
October 25, 2019
Polyfunctional tumor-reactive T cells are effectively expanded from non-small cell lung cancers, and correlate with an immune-engaged T cell profile
Rosa De Groot, Marleen M Van Loenen, Aurélie Guislain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 19, 2022
PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC
Karlijn Hummelink, Vincent van der Noort, Mirte Muller, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 18, 2024
Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohort
J W T van der Wel, M Jebbink, D van den Broek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 7, 2024
ESMO Recommendations on clinical reporting of genomic test results for solid cancers
J van de Haar, P Roepman, F Andre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 1, 2025
Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol
Karlijn Verkerk, Soemeya F Haj Mohammad, Laurien J Zeverijn, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
November 25, 2023
Impact of genetic counseling strategy on diagnostic yield and workload for genome-sequencing-based tumor diagnostics
Roelof Koster, Luuk J Schipper, Noor A A Giesbertz, et al.
Lung Cancer (Amsterdam, Netherlands)
|
July 1, 2026
Prevalence and characteristics of NTRK fusions in 25,946 patients with non-small cell lung cancer
Teodora Radonic, Sepehr Rahmani-Khajouei, Urania Dafni, et al.
JTO Clinical and Research Reports
|
August 12, 2025
Longitudinal Circulating Tumor DNA-Guided Resistance Analysis During Second-Line Osimertinib Treatment
J W Tijmen van der Wel, Merel Jebbink, Vincent van der Noort, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 1, 2021
Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project
Stephen P Finn, Alfredo Addeo, Urania Dafni, et al.
Page
of 16
Search research articles
Search
Showing results (121-130 of 160) with videos related to
Sort By:
Page
of 16
Plos One
|
May 25, 2019
Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer
Willemijn S M E Theelen, Thomas Kuilman, Katja Schulze, et al.
Oncoimmunology
|
October 25, 2019
Polyfunctional tumor-reactive T cells are effectively expanded from non-small cell lung cancers, and correlate with an immune-engaged T cell profile
Rosa De Groot, Marleen M Van Loenen, Aurélie Guislain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 19, 2022
PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC
Karlijn Hummelink, Vincent van der Noort, Mirte Muller, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 18, 2024
Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohort
J W T van der Wel, M Jebbink, D van den Broek, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 7, 2024
ESMO Recommendations on clinical reporting of genomic test results for solid cancers
J van de Haar, P Roepman, F Andre, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 1, 2025
Checkpoint Blockade Combinations in Tumor Mutational Burden/Load-High Tumors: Insights from the Atezolizumab + Bevacizumab and Nivolumab + Ipilimumab Cohorts in the Drug Rediscovery Protocol
Karlijn Verkerk, Soemeya F Haj Mohammad, Laurien J Zeverijn, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
November 25, 2023
Impact of genetic counseling strategy on diagnostic yield and workload for genome-sequencing-based tumor diagnostics
Roelof Koster, Luuk J Schipper, Noor A A Giesbertz, et al.
Lung Cancer (Amsterdam, Netherlands)
|
July 1, 2026
Prevalence and characteristics of NTRK fusions in 25,946 patients with non-small cell lung cancer
Teodora Radonic, Sepehr Rahmani-Khajouei, Urania Dafni, et al.
JTO Clinical and Research Reports
|
August 12, 2025
Longitudinal Circulating Tumor DNA-Guided Resistance Analysis During Second-Line Osimertinib Treatment
J W Tijmen van der Wel, Merel Jebbink, Vincent van der Noort, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 1, 2021
Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project
Stephen P Finn, Alfredo Addeo, Urania Dafni, et al.
Page
of 16